GNBT – BioPharma w/10x Potential – Cancer and Diabetes Treatments – Nasdaq Up List

Under $2 PPS With Potential To Over $10 In Near Term
Phase III Trials On Horizon For Cancer and Diabetes
Nasdaq Up List Targeted Before End Of Year
Dividend Strategy

October 31, 2019 -- InvestorsHub NewsWire -- via www.nextbigticker.com -- Generex Biotechnology Corporation (www.generex.com) (GNBT) is sitting on an explosive ROI opportunity with a price-per-share (PPS) under $2.00 and a potential to see over $10.00 by the end of this year. GNBT is simultaneously advancing multiple bull run triggers – Phase III trials for cancer and diabetes treatments; A pending Nasdaq up-listing, and stock dividend. The Nasdaq up-list will bring GNBT an institutional investor base it does not currently enjoy as a bulletin-board stock. Phase III biopharma trials regularly drive a massive market-cap increase on the magnitude of 10x making biopharma one of the top performing sectors consistently outperforming other sectors. GNBT has demonstrated a dividend strategy and has a dividend on the books now pending the completion of its Nasdaq up-list.

Global demand for Biopharmaceuticals is projected to grow at a CAGR of 10.8% between 2018 and 2025. The global market for biopharmaceuticals in 2019 is expected to reach US$269.3 billion. The biopharmaceuticals market is driven largely by an increase in the elderly population, a surge in the prevalence of chronic diseases like cancer, HIV/AIDS and diabetes. Biopharmaceuticals offer the potential to actually cure diseases rather than merely treat the symptoms. Hence the market demand for biopharmaceuticals.

Drug company valuations increase exponentially over time. The valuations start to become interesting when a company enters Phase II trials which GNBT is now well into. Drug companies that transition from Phase II to Phase III regularly see valuations go from under $100 million to over $1 billion. GNBT is sitting at a market-cap today of approximately $70 million. It takes a long time to develop drugs, and most of the value is created after many years. GNBT is not a new company. It is a 20-year-old company that has upped its game and expanding into managing healthcare networks in addition to continuing to develop its portfolio of drugs. The healthcare management provides GNBT a unique sustainability model not seen in other biopharma companies. Yet another reason to make a bet on GNBT’s long-term ROI potential.

GNBT is an investment opportunity worth your time to explore.

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com